{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-059749","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2026-05-13T10:57:15+00:00","discovered_at":"2026-05-13T11:00:00.388108+00:00","generated_at":"2026-05-13T11:04:40.232979+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protalix BioTherapeutics Reports First Quarter 2026 Financial Results and Reaffirms Guidance","bullets":["Received $25 million milestone from Chiesi following European Commission approval of Elfabrio 2 mg/kg every-4-weeks dosing regimen.","PRX-115 Phase 2 RELEASE study for uncontrolled gout continues; top-line results expected second half of 2027.","Reaffirms 2026 revenue guidance of $78.0-$83.0 million including $25 million milestone; Elfabrio sales $33-$35 million, Elelyso $20-$23 million.","Cash and equivalents $51 million as of March 31, 2026; no outstanding debt or warrants."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-059749","json":"https://secwatch.observer/filing/0001104659-26-059749.json","markdown":"https://secwatch.observer/filing/0001104659-26-059749.md","text":"https://secwatch.observer/filing/0001104659-26-059749.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000110465926059749/0001104659-26-059749-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000110465926059749/plx-20260513x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-13T11:04:40.232979+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d49078e209939131c0c687b49040cf11f37bdd1e","claim":"Protalix BioTherapeutics, Inc. updated its the first quarter ended March 31, 2026 guidance (reaffirmed).","evidence_excerpt":"Protalix BioTherapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465926059749/0001104659-26-059749-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}